← Leaderboards
Mark Louis Brantly
University Of Florida
$2,016,455
Attributed
$2,016,455
Total exposure
31
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $573.1K · FY2005–09$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$2,016,455 · 31
By mechanism
M01$1,345,980 · 30
K24$670,475 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Florida
Same institution · by research overlap
- Terence R. Flotte$26,412,339
- Charles H Hubscher$8,534,688
- Sihong Song$1,714,919
- Thomas J. Kodadek$29,218,794
- L T Spencer$1,014,888
Others in their field
Top investigators on “Grant”
- David R. Weir · University Of Michigan At Ann Arbor$373,949,788
- David Heimbrook · Leidos Biomedical Research, Inc.$341,196,902
- Eric S Lander · Whitehead Institute For Biomedical Res$323,181,457
- Jeffrey P Krischer · University Of South Florida$258,583,867
- Lawrence Corey · Fred Hutchinson Cancer Center$253,286,867
- Barton F Haynes · Duke University$243,251,908
Research focus
GrantInstitutionResourcesComputer Retrieval Of Information On Scientific Projects DatabaseResearch PersonnelUnited States National Institutes Of HealthFundingClinical ResearchSourceHuman SubjectAlpha 1-AntitrypsinAlpha 1 AntitrypsinClinical TrialsPulmonary Function TestsRandomizedFollow-UpChronic Obstructive Airway DiseaseWeekResponseAlpha 1 Antitrypsin DeficiencySafetyScreening ProcedurePharmaceutical PreparationsInterleukin 8
Grant awards (37)
CLINICAL TRIAL: PHASE I TRIAL OF INTRAMUSCULAR INJECTION OF RAAV1-CB-HAAT$11,930
M01 · FY2009 · RR · contact PI
ALPHA-1 ANTITRYPSIN AND MACROPHAGE FUNCTION$9,908
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE 3 STUDY OF SAFETY AND EFFICACY OF PIRFENIDONE IN PATIENTS$6,268
M01 · FY2009 · RR · contact PI
QUANTUM$4,448
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: KAMADA-API$3,640
M01 · FY2009 · RR · contact PI
THE MILES TRIAL$2,831
M01 · FY2009 · RR · contact PI
PIRFENIDONE AND PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)$809
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: TOBACCO SMOKE INDUCED CELL INJURY IN LUNG COMPARTMENTS$202
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: KAMADA-API$128,448
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE 3 STUDY OF SAFETY AND EFFICACY OF PIRFENIDONE IN PATIENTS$29,267
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE I TRIAL OF INTRAMUSCULAR INJECTION OF RAAV1-CB-HAAT$26,556
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: TOBACCO SMOKE INDUCED CELL INJURY IN LUNG COMPARTMENTS$24,930
M01 · FY2008 · RR · contact PI
ALPHA-1 ANTITRYPSIN AND MACROPHAGE FUNCTION$9,756
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: CHAMP$6,504
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: STAMP$2,710
M01 · FY2008 · RR · contact PI
CHAMP$46,632
M01 · FY2007 · RR · contact PI
TOBACCO SMOKE INDUCED CELL INJURY IN LUNG COMPARTMENTS$39,665
M01 · FY2007 · RR · contact PI
STAMP$23,048
M01 · FY2007 · RR · contact PI
GENETIC MODIFIERS OF THE ALPHA1-ANTITRYPSIN DEFICIENCY$3,751
M01 · FY2007 · RR · contact PI
PHASE 3 STUDY OF SAFETY AND EFFICACY OF PIRFENIDONE IN PATIENTS WITH IPF$535
M01 · FY2007 · RR · contact PI
Anti-Inflammatory Role of Alpha-1 Antitrypsin in Lung$134,095
K24 · FY2006 · HL · contact PI
GENETIC MODIFIERS OF THE ALPHA1-ANTITRYPSIN DEFICIENCY$1,981
M01 · FY2006 · RR · contact PI
FINE MAPPING OF COPD SUSCEPTIBILITY GENES$1,321
M01 · FY2006 · RR · contact PI
EFFECT OF AERO, RECOMB ALPHA 1-ANTITRYPSIN DEF ON EPITHELIAL LINING FLUID$432,156
M01 · FY2005 · RR
Anti-Inflammatory Role of Alpha-1 Antitrypsin in Lung$134,095
K24 · FY2005 · HL
UNIVERSITY OF FLORIDA CLINICAL RESEARCH CENTER DNA, SERUM AND PLASMA BANK$3,390
M01 · FY2005 · RR
GENETIC MODIFIERS OF THE ALPHA1-ANTITRYPSIN DEFICIENCY$2,739
M01 · FY2005 · RR
FINE MAPPING OF COPD SUSCEPTABILITY GENES$684
M01 · FY2005 · RR
Phase 1 safety invest of an aerosolized, recomb A1 antitrypsin in subj w/ A 1$188,909
M01 · FY2004 · RR
The Effects of Atorvastatin on Immune Responses to Tetanus Vaccination$163,187
M01 · FY2004 · RR
4-phenyl butyrate mediated secretion rescue in alpha 1 antitrypsin deficiency$139,874
M01 · FY2004 · RR
Anti-Inflammatory Role of Alpha-1 Antitrypsin in Lung$134,095
K24 · FY2004 · HL
The Pharmacokinetics and Safety Of An Alpha-1 Proteinase Inhibitor (ARC-API)$24,919
M01 · FY2004 · RR
Genetic Modifiers of the Alpha1-Antitrypsin Deficiency$3,215
M01 · FY2004 · RR
University of Florida Clinical Research Center DNA, Serum and Plasma Bank$1,767
M01 · FY2004 · RR
Anti-Inflammatory Role of Alpha-1 Antitrypsin in Lung$134,095
K24 · FY2003 · HL
Anti-Inflammatory Role of Alpha-1 Antitrypsin in Lung$134,095
K24 · FY2002 · HL